Picture of Lineage Cell Therapeutics logo

LCTX Lineage Cell Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapSucker Stock

Annual cashflow statement for Lineage Cell Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-11.7-20.6-43-26.3-21.5
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items-21.5-2.52-2.517.94.83
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-1.91.321.118.7-10.8
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-31.9-19.8-23.61.06-28.6
Capital Expenditures-0.44-0.064-0.354-0.413-0.674
Purchase of Fixed Assets
Other Investing Cash Flow Items17.413.110.1-45.747.1
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities17139.74-46.246.4
Financing Cash Flow Items0.654-0.383-1.16-0.123-0.236
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities0.61729.936.91.636.42
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-14.323.123.1-44.324.1